Publication

Population Pharmacokinetics of Tamibarotene in Pediatric and Young Adult Patients with Recurrent or Refractory Solid Tumors

Find out how PopPK modelling supports precise tamibarotene dosing in pediatric and young adult solid…

CertaraNovember 14, 2024

Publication

A Pharmacokinetic/Toxicodynamic Model of Cisplatin Nephrotoxicity Using the Kidney Injury Molecule‑1 Biomarker

Discover how PK‑TD modelling shows palonosetron reduces platinum exposure and KIM‑1 elevations versus other antiemetics…

CertaraSeptember 20, 2024

Publication

Population pharmacokinetic model for oral ORIN1001 in Chinese patients with advanced solid tumors

Discover how PopPK modelling supports dose‑adjustment considerations for ORIN1001 based on bilirubin and lean body…

CertaraMarch 4, 2024

Publication

Pharmacokinetic – toxicodynamic Modeling to Elucidate the Involvement of Dorsal Root Ganglion Neuron in Oxaliplatin – induced Peripheral Neurpathu

See how DRG‑based PK‑TD modelling predicts neuropathy severity and supports safer oxaliplatin dosing strategies using…

CertaraFebruary 1, 2024

Publication

Population Pharmacokinetics and Pharmacogenetics Analyses of Dasatinib in Chinese Patients with Chronic Myeloid Leukemia

Explore how age increases dasatinib exposure; PopPK modelling supports lower dosing in elderly Chinese CML…

CertaraSeptember 19, 2023

Publication

Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation

Discover how hemoglobin and eGFR drive imatinib PK variability; PopPK modelling supports caution in renal…

CertaraAugust 25, 2023

Publication

Population pharmacokinetic analysis of TQ-B3203 following intravenous administration of TQ-B3203 liposome injection in Chinese patients with advanced solid tumors

See how PopPK modelling shows bilirubin, BMI, and lean body weight meaningfully affect TQ‑B3203 clearance…

CertaraJanuary 16, 2023

Publication

Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients

See how early clearance drop predicts better response and survival; PopPK built using Phoenix NLME.

CertaraSeptember 6, 2022

Publication

Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: A single-center, open-label phase I trial.

Discover how itraconazole markedly increases SHR2554 exposure; PK interaction assessed using Phoenix WinNonlin.

CertaraJuly 16, 2022

Publication

Co-Administration with Voriconazole Doubles the Exposure of Ruxolitinib in Patients with Hematological Malignancies

Find out how voriconazole more than doubles ruxolitinib exposure, supporting dose adjustment guidance for hematologic…

CertaraMarch 25, 2022

Oncology

Population Pharmacokinetics of Tamibarotene in Pediatric and Young Adult Patients with Recurrent or Refractory Solid Tumors

A Pharmacokinetic/Toxicodynamic Model of Cisplatin Nephrotoxicity Using the Kidney Injury Molecule‑1 Biomarker

Population pharmacokinetic model for oral ORIN1001 in Chinese patients with advanced solid tumors

Pharmacokinetic – toxicodynamic Modeling to Elucidate the Involvement of Dorsal Root Ganglion Neuron in Oxaliplatin – induced Peripheral Neurpathu

Population Pharmacokinetics and Pharmacogenetics Analyses of Dasatinib in Chinese Patients with Chronic Myeloid Leukemia

Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation

Population pharmacokinetic analysis of TQ-B3203 following intravenous administration of TQ-B3203 liposome injection in Chinese patients with advanced solid tumors

Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients

Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: A single-center, open-label phase I trial.

Co-Administration with Voriconazole Doubles the Exposure of Ruxolitinib in Patients with Hematological Malignancies

Newsletter sign up

Quick links

Solutions

Contact